Immunic Inc (IMUX NASDAQ) stock market data APIs
$0.6684
0.02(3%)
as of December 5, 2025
Try our APIs with
free plan!
Immunic Inc Financial Data Overview
Price chart is built with
Anychart
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Prev. Close
0.6684
Open
0.6925
High
0.6998
Low
0.6662
52 wk Range
0.561-1.39
Market Cap
79 941 K
Shares Outstanding
120 M
EPS
-0.13
Beta
1.485
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunic Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunic Inc data using free add-ons & libraries
Get Immunic Inc Fundamental Data
Immunic Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -105 371 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunic Inc News
New
Immunic GAAP EPS of -$0.13 beats by $0.06
* Immunic press release [https://seekingalpha.com/pr/20305667-immunic-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (IMUX [https://seekingalpha.com/symbol/IMUX]): Q...
Datadog, Trade Desk upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: K...
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Confer...
Immunic board authorizes up to 35 million stock appreciation rights for employees
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $80 million, announced that on Monday its board of directors authorized grants of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
